S. Louise Phanstiel

Chair of the Board

S. Louise Phanstiel, Chair of the Board of Directors, has been a director of Myriad since September 2009, held several executive positions at Anthem, Inc., formerly WellPoint, Inc. from 1996 to 2007.  She was President, Specialty Products which included behavioral health services; Senior Vice President, Chief of Staff and Corporate Planning in the Office of the Chairman; and Chief Accounting Officer, Controller and Chief Financial Officer for all WellPoint, Inc. subsidiaries.  Previously, Ms. Phanstiel was a partner at the international services firm PricewaterhouseCoopers, LLP, formerly Coopers & Lybrand, LLP where she specialized in insurance.  Ms. Phanstiel’s life science experience includes having previously served on the Board of Directors and Chair of the Audit Committees at publicly traded companies, Inveresk Research Group, Inc. and Verastem, Inc.

Paul J. Diaz


Paul J. Diaz, was named president, chief executive officer and member of the Myriad board of directors on August 13, 2020. Paul was most recently a partner at Cressey & Company (2016-2020), a private investment firm headquartered in Chicago, Illinois, which currently manages over $3.0 billion in committed capital. Cressey & Company is a healthcare focused middle-market private equity firm with over 30 years of success investing in and helping to build high quality healthcare businesses.Read More

Heiner Dreismann Ph.D.


Heiner Dreismann, Ph.D., joined the company in June 2010. Dr. Dreismann had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies. He earned a master of science degree in biology and his doctor of philosophy degree in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany.

Rashmi Kumar


Rashmi Kumar was named a Director of Myriad Genetics in September 2020.  Currently, she serves as Senior Vice President and Chief Information Officer, Global IT, at Hewlett Packard Enterprise.  Prior to that, she was SVP and CIO, U.S Pharmaceutical, at McKesson and served in senior leadership roles for large enterprises including Southern California Edison, Toyota, and Tata Steel.  She earned a Bachelor’s degree in metallurgical engineering from Bihar Institute of Technology in Sindri, India and a M.B.A. from University of California, Irvine’s Paul Merage School of Business.

Dennis Langer M.D, J.D.


Dennis Langer, M.D., J.D. is a Director of the company as of May 2004. He was previously Senior Vice President in Research and Development at GlaxoSmithKline and has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and GD Searle. He is also a Clinical Professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer has earned a J.D. (cum laude) from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.

Lee N. Newcomer M.D.


Lee N. Newcomer, M.D., board-certified medical oncologist, joined the company in September 2019. Most recently, he was Senior Vice President of Oncology and Genetics for UnitedHealthcare. Previously, he served as Chief Medical Officer and Senior Vice President of Health Policy and Strategy at UnitedHealth Group, and Chief Medical Officer at Vivius, Inc. Dr. Newcomer earned a M.D. from University of Nebraska College of Medicine, a M.H.A from University of Wisconsin-Madison and a B.A. from Nebraska Wesleyan.

Colleen F. Reitan


Colleen F. Reitan joined the company in September 2019. Most recently, she served as President of Plan Operations for Healthcare Service Corporation (HCSC). Prior to that, she held several roles, including serving as the Executive Vice President and Chief Operating Officer of HCSC and President and Chief Operating Officer of Blue Cross & Blue Shield of Minnesota. She previously served on boards at Availity LLC, MEDecision, Inc. and Prime Therapeutics LLC. Reitan has a M.H.A. from the University of Minnesota and a B.A. in Urban Studies and Economics from Minnesota State University.

Daniel M. Skovronsky


Daniel M. Skovronsky, M.D., Ph.D., joined the company as a Director in July 2020. Currently, he serves as Chief Science Officer and President of Lilly Research Laboratories at Eli Lilly and Company. Previously, he was Chief Executive Officer of Avid Radiopharmaceuticals Inc., a company he founded in 2004. Dr. Skovronsky earned his M.D. from the Perelman School of Medicine, University of Pennsylvania, his Ph.D. in neuroscience from University of Pennsylvania and a B.S. in molecular biophysics and biochemistry from Yale University.

Daniel K. Spiegelman


Daniel K. Spiegelman has been a Director of the company since May 2020. Most recently, he served as Executive Vice President and Chief Financial Officer at BioMarin Pharmaceuticals, Inc. Prior to that, he held several roles, including Senior Vice President and Chief Financial Officer of CV Therapeutics and Treasurer at Genentech, Inc. He is currently a member of the board of directors at Tizona Therapeutics, Inc., a private pharmaceutical company. Mr. Spiegelman received a B.A. degree from Stanford University and a M.B.A. from the Stanford Graduate School of Business.